Toronto, Canada — Inhaled cannabis is effective and well-tolerated in patients with Tourette’s Syndrome (TS), according to clinical data published online ahead of print in the Journal of Neuropsychiatry and Clinical Neuroscience.
A team of researchers at the University of Toronto retrospectively assessed the safety and efficacy of inhaled cannabis in 19 patients with the disease.
Researchers reported, “All study participants experienced clinically significant symptom relief,” including reductions in obsessive-compulsive symptoms, impulsivity, anxiety, irritability, and rage outbursts. Eighteen of the 19 patients experienced decreased tic severity. Cannabis was “generally well tolerated” by study subjects.
Investigators concluded: “Overall, these study participants experienced substantial improvements in their symptoms. This is particularly striking given that almost all participants had failed at least one anti-tic medication trial. … In conclusion, cannabis seems to be a promising treatment option for tics and associated symptoms.”
Placebo controlled data has previously determined that oral THC dosing also improves tics and obsessive-compulsive behavior in TS patients. However, patients utilizing inhaled cannabis have generally shown greater overall improvement.
For more information, please contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette Syndrome,” appears in the Journal of Neuropsychiatry and Clinical Neuroscience.